Inception of Electro-Nucleonics, Inc. (ENI) to do research and
development in gas centrifuge technology.
ENI introduces its Model K™ ultracentrifuge, and the first
centrifugal clinical chemistry blood analyzer, GEMSAEC™.
Electro-Nucleonics Laboratories, Inc. (ENLI) organized to apply
our ultracentrifugation technology to biophysical separations.
The privately financed construction of Cell Science Laboratory
by ENI is completed.
Introduced GEMENI®, the first chemistry analyzer to bring
microprocessor-based testing into the hospital.
Introduced RIAUSURE II®, the automated hepatitis B test.
FLEXIGEM™ is introduced to offer clinical chemistry testing
in the mid to large hospital laboratory.
Princeton Biomedix is acquired from Becton Dickinson & Co.
Its chemistry reagent manufacturing capability adds strength to
ENI’s growing position as a fully integrated supplier of
medical diagnostics systems.
GEMSTAR™ introduced as first profile analyzer for physicians'
office testing.
ENI is one of 5 companies selected by the FDA to develop a blood
screening test for AIDS.
ENI is the second company to receive a license to market its screening
test for HTLV-III, the AIDS-linked virus.
ENI acquired by Pharmacia AB of Upsala, Sweden. The company is
renamed Pharmacia Diagnostics, Inc.
Pharmacia Diagnostics sells the Clinical Chemistry and Centrifuge
business to Alfa Schiapparelli Wassermann. The company is renamed
Schiapparelli Biosystems, Inc.
ACE™, discrete, random access centrifugal clinical chemistry
system launched. First system of its kind to incorporate CLIA
’88 compliant features.
NExCT™ clinical chemistry system launched. Designed for lower
volume labs as the ideal balance of low cost and high quality.
Launched the SmartConsole control system for automated process
operations incorporating distinctive features such as batch control,
data recording, and safety monitoring with KII ultracentrifuge
technology.
Launch of Pilot System KII for research scale and pilot plant
processes with linear scale capabilities, and SmartSystem KII
for large volume production applications.
Initiated Genomics program for value-added healthcare products
capitalizing on the global human genome effort.
Company name changed to Alfa Wassermann, Inc. in conjunction with
global alignment of all divisions with parent company.
Move to new headquarters in West Caldwell, New Jersey.
Alfa Wassermann receives the NorthFace Award for customer excellence from the Omega Management Group.
Alfa Wassermann receives ISO 9001:2000 Certificate.
Alfa Wassermann receives the NorthFace Award for customer excellence from the Omega Management Group for the second consecutive year.
Alfa Wassermann launches the ACE Alera® clinical chemistry system.
Alfa Wassermann receives the NorthFace Award for customer excellence from the Omega Management Group for the third consecutive year.
Alfa Wassermann receives the NorthFace Award for customer excellence from the Omega Management Group for the fourth consecutive year.
Alfa Wassermann receives the NorthFace Award for customer excellence from the Omega Management Group for the fifth consecutive year.
